1. Triantafillidis JK, Mylonaki M, Georgopoulos F. Nocturnal acid breakthrough: consequences and confronting. Annals Gastroenterol 2003; 16: 281-287.

2. Triantafillidis JK, Mylonaki M. Is there any place for the chimeric antibody against tumor necrosis factor (infliximab) in the treatment of patients with active ulcerative colitis? Annals Gastroenterol 2004; 17: 145-152.

3. Triantafillidis JK, Stamataki A, Gikas A, Sklavaina M, Mylonaki M, Georgopoulos F, Mastrangelis A, Cherakakis P. Beneficial affect of a polymeric feed rich in TGF-β on adult patients with active Crohn’s disease: a pilot study. Ann Gastroenterol 2006; 19: 66-71.

4. Cherakakis P, Parasi A, Karambelis A, Tzouvala M, Mylonaki M, Georgopoulos F, Mastrangelis A, Triantafillidis JK. Primary malignant esophageal melanoma. Diagnostic and therapeutic manipulation of a Greek patient and review of the literature. Ann Gastroenterol 2006; 19: 85-95.

5. Triantafillidis JK Cherakakis P, Georgopoulos F, Mylonaki M. Manousakis K, Giannakoulopoulou E, Vaslatzidou A, Malgarinos G, Mastrangelis A, 40 Fouskas J, Peros G. Obstructive uropathy in Crohn’s disease: description of two cases and review of the literature. Ann Gastroenterol 2006; 19: 292- 297.

6. J.K. Triantafillidis, P. Cheracakis, F. Georgopoulos, Maria Mylonaki, K. Giannakoulopoulou, A. Mastrangelis, G. Malgarinos, J. Fouskas, A. Varlatzidou, G. Peros. Ileovesical fistulas in Crohn’s disease: Clinical features and therapeutic manipulations in 5 patients Ann Gastroenterol 2006;19:342-346.

7. J. K. Triantafillidis, P. Cheracakis,G. Malgarinos, Maria Mylonaki, F. Georgopoulos. Myocarditis due to mesalamine treatment in a patient with ulcerative colitis: Favorable short and long-term outcome after infliximab treatment. Annals Gastroenterology 2009;22(1):62-64.